The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication

Wanyu Deng\textsuperscript{1,2}, Mengji Lu\textsuperscript{2*}

\textsuperscript{1}. College of Life Science, Shangrao Normal University, Shangrao 334001, China
\textsuperscript{2}. Institute of Virology, University Hospital of Essen, University of Duisburg-Essen, Essen 45147, Germany

Though efficient vaccines against hepatitis B virus (HBV) and antiviral therapies are available, chronic HBV infection is still a global health problem. The process of HBV infection and HBV life cycle are extensively studied in last decades, however, the mechanisms of HBV-induced alterations of host cell metabolisms and host factors involved in modulating of viral replication are not fully understood. Thus, it is an important issue to examine these specific HBV-host interactions for development of novel strategies for antiviral therapies. Recently, microRNAs (miRNAs), a class of post-transcriptional regulatory small RNA, seem to be the relevant fine tuning factors of various cellular activities and pathways, including cell growth, metabolism, and viral replication. In this review, we summarize the up to date knowledge concerning the virus-host interactions and emphasizing on the role of miRNAs in regulation of HBV replication and host cell metabolism.

KEYWORDS microRNA; HBV replication; hepatocytes; cell metabolism; transcription factors

INTRODUCTION

MicroRNAs (miRNAs) are a class of endogenous short-stranded RNA that control target gene expression by binding to partially complementary sequences within the 3’ untranslated region (UTR) of specific mRNAs (Bartel, 2004). Although the exact functions for each miRNA is not fully exploited, it is suggested that a single miRNA may simultaneously target more than 100 mRNAs according to target databases based primarily on Watson-Crick base-pairing (Rottiers and Naar, 2012). Currently, more than 2000 miRNAs have been identified in humans and it is believed that they collectively regulate one third of the genes in the genome (Hammond, 2015). The liver is a primary organ of metabolism. Viral infection and abnormal metabolism may cause chronic liver disease and could lead to hepatocellular carcinoma (HCC). A great number of studies indicate a pivotal role of miRNAs in tumor progress, including HCC. They can act both as tumor suppressors and oncogenes by targeting various relevant genes, thereby contributing to cell proliferation and metastasis pathways. A certain stability of miRNAs in peripheral blood makes them to be ideal candidates for diagnosis of cancers (Chu et al., 2014; Sidhu et al., 2015).

Hepatitis B virus (HBV) causes acute or chronic infection and also systematic metabolic alterations in hepatocytes. The majority of acutely HBV-infected patients recover. However, some cases may progress to chronicity and the risk for developing chronic HBV infection (CHB) is significantly higher for infants than adults (Schweitzer et al., 2015). CHB is considered to be a global public health issue since it is associated with chronic hepatitis, cirrhosis, and HCC. According to the data published from 1965 to 2013, the prevalence of HBsAg is 3.61% worldwide and about 5.49% in China (Schweitzer et al., 2015). The clinical intervention using interferon and/or nucleotide analogs to treat chronically HBV-infected patients could efficiently suppress viral replication, however, the currently available therapies do not lead to the termination of HBV infection in the ma-
miRNAs ARE INVOLVED IN GLUCOSE METABOLISM

miRNAs have recently been implicated in controlling glucose metabolism at multiple levels. In HCC tissues, miR-122 may mediate glycolytic activities through targeting pyruvate kinase M2 (PKM2), an isoform of pyruvate kinase that catalyzes the transfer of a phosphoryl group from phosphoenolpyruvate to ADP, generating ATP and pyruvate (Liu et al., 2014). The development of HCC is also accompanied by a significant reduction of serum insulin-like growth factor (IGF-1) levels. IGF-1 is produced mainly by the liver and represents a target of miR-190b. An increased expression of miR-190b may cause decreased IGF-1 and poor overall survival in HCC patients (Hung et al., 2014). Both miR-125b and -199a-5p target hexokinase II (HK2), an enzyme that catalyzes the irreversible first step of glycolysis in the liver, thereby suppressing glucose consumption (Jiang et al., 2014; Guo et al., 2015). Obesity-induced overexpression of miR-143 and −802 also impairs glucose metabolism through silencing of hepatocyte nuclear factor 1 beta (HNF1β) and inhibiting insulin-stimulated serine/threonine protein kinase (AKT) activation (Jordan et al., 2011; Kornfeld et al., 2013). Moreover, the overexpression of miR-214 in primary hepatocytes suppresses glucose production by targeting activating transcriptional factor 4 (ATF4) (Li et al., 2015b). Finally, miR-491-3p targets one of UDP-glucuronosyltransferases (UGT) 1A isoforms, which are highly expressed in the liver involved in the glucose metabolism and glucuronidation activity (Dluzen et al., 2014).

miRNAs ARE INVOLVED IN LIPID METABOLISM

Several miRNAs have been described to regulate lipid metabolism, including miR-122 which is highly expressed in liver, estimated to account for approximately 70% of all liver miRNA (Lagos-Quintana et al., 2002; Krutzfeldt et al., 2005). MiR-122 inhibition resulted in increased hepatic fatty-acid oxidation and a reduced cholesterol synthesis by 25 to 35% in the mouse model (Esau et al., 2006). Knockdown of miR-24 in high-fat diet-treated mice caused impaired hepatic lipid accumulation and reduced plasma triglycerides through regulating the target gene insulin-induced gene 1 (INSIG1). INSIG1 is a lipogenesis inhibitor that participates in the processing of lipid synthesis transcription factors sterol regulatory element binding proteins (SREBPs) (Ng et al., 2014). Mattis et al. (2015) identified miR-29a as the miRNA responsible for repressing lipoprotein lipase (LPL) in hepatocytes, which encodes an enzyme that facilitates cellular uptake of lipids from the circulation. A decreased hepatic miR-29a level causes lipids to accumulate in the mouse liver tissue. Besides, miR-33, which is located within the coding region of SREBPs and co-transcribed with them, also regulates cholesterol and fatty acid metabolism (Najafi-Shoushtari et al., 2010; Davalos et al., 2011; Rayner et al., 2011). miR-1, -206, and -613 target the nuclear receptor subfamily 1 group H member 3 (NR1H3, also known as LXRA), which plays a critical role in the transcriptional control of lipid metabolism through inducing the expression of lipogenic genes. These miRNAs repress LXRA-induced accumulation of lipid droplets in hepatocytes, accompanied with the inhibition of the expression of LXRA-regulated genes, such as SREBP1, fatty acid synthase (FAS), carbohydrate responsive element-binding protein (ChREBP), and acetyl-CoA carboxylase (ACC) (Zhong et al., 2013a; 2013b). Other miRNAs like miR-27a (Shirasaki et al., 2013), -106b (Kim et al., 2012), -302a (Hoekstra et al., 2013), -373 (Nakanishi et al., 2009), -370 (Iliopoulos et al., 2010), -378/378* (Gerin et al., 2010), and -758 (Ramirez et al., 2011) have also been shown to regulate lipid homeostasis through targeting transcription factors related to lipid metabolism.

HBV INFECTION CAUSES METABOLIC ALTERATION IN HOST CELLS

HCC development is often associated with HBV infection. It is reported that 69% of liver cancer cases in Asia are related to chronic HBV infection (Iavarone and Colombo, 2013). Metabolic alterations may be induced by HBV infection and are associated with carcinogenesis. The cancer cells often reveal higher glycolysis rate in comparison to normal liver tissue, accompanied with increased glucose consumption, decreased oxidative phosphorylation, and increased lactate production to support the increased demand of macromolecules for cell growth and proliferation (Hsu and Sabatini, 2008). In vitro and in vivo experiments showed that the host cellular glycogen level could be decreased through the interaction between HBV large surface protein and acid alpha-glucosidase (GAA), which is essential for the degradation of glycogen and plays an important role in glycogen balance (Hung et al., 2010; Teng et al., 2015). The biosynthesis of hexosamine and phosphatidylcholine could be up-regulated by activating glutamine-fructose-6-phosphate metabolism and reduced plasma triglycerides through regulating the target gene insulin-induced gene 1 (INSIG1). INSIG1 is a lipogenesis inhibitor that participates in the processing of lipid synthesis transcription factors sterol regulatory element binding proteins (SREBPs) (Ng et al., 2014). Mattis et al. (2015) identified miR-29a as the miRNA responsible for repressing lipoprotein lipase (LPL) in hepatocytes, which encodes an enzyme that facilitates cellular uptake of lipids from the circulation. A decreased hepatic miR-29a level causes lipids to accumulate in the mouse liver tissue. Besides, miR-33, which is located within the coding region of SREBPs and co-transcribed with them, also regulates cholesterol and fatty acid metabolism (Najafi-Shoushtari et al., 2010; Davalos et al., 2011; Rayner et al., 2011). miR-1, -206, and -613 target the nuclear receptor subfamily 1 group H member 3 (NR1H3, also known as LXRA), which plays a critical role in the transcriptional control of lipid metabolism through inducing the expression of lipogenic genes. These miRNAs repress LXRA-induced accumulation of lipid droplets in hepatocytes, accompanied with the inhibition of the expression of LXRA-regulated genes, such as SREBP1, fatty acid synthase (FAS), carbohydrate responsive element-binding protein (ChREBP), and acetyl-CoA carboxylase (ACC) (Zhong et al., 2013a; 2013b). Other miRNAs like miR-27a (Shirasaki et al., 2013), -106b (Kim et al., 2012), -302a (Hoekstra et al., 2013), -373 (Nakanishi et al., 2009), -370 (Iliopoulos et al., 2010), -378/378* (Gerin et al., 2010), and -758 (Ramirez et al., 2011) have also been shown to regulate lipid homeostasis through targeting transcription factors related to lipid metabolism.
amidotransferase 1 (GFAT1) and choline kinase alpha (CHKA) in hepatoma cells with HBV replication, respectively (Li et al., 2015a). Besides, HBV infection also induces lipid metabolic alteration. Abnormal lipid metabolism is considered as a hallmarker of tumorgenesis (Shi et al., 2016). The lipid metabolism-related genes, LXR, SREBP1, peroxisome proliferator-activated receptor alpha (PPARA), PPARG, HNF3B, and CCAAT/enhancer binding protein alpha (CEBPA) were identified to be significantly activated in hepatoma cells transfected with HBx or in HBx transgenic mice (Kim et al., 2007; Na et al., 2009; Wu et al., 2015; Xu et al., 2016). The cholesterol 7 alpha-hydroxylase (CYP7A), which catalyzes the first reaction in the cholesterol catabolic pathway in the liver, acts as the rate limiting step and the major site of regulation of bile acid synthesis. CYP7A and other cholesterol synthesis associated genes, including SREBF2, 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMGCR), and low-density lipoprotein receptor (LDLR) were also found to be enhanced in HBV-infected human liver tissue in the chimeric mouse model (Oehler et al., 2014).

HOST METABOLIC FACTORS PARTICIPATE IN HBV REPLICATION

HBV is a small enveloped DNA virus, which contains a partially double stranded, relaxed circular DNA (rcDNA) in viral particles. The HBV rcDNA could be completed to form covalently closed circular DNA (cccDNA) in the cell nucleus likely by viral polymerase, assisted by certain host enzymes. The cccDNA serves as the template for transcription of pregenomic RNA (pgRNA) and three subgenomic RNA (sgRNA), including precore RNA, S RNA, and X RNA. The transcripts are then exported to cytoplasm and translated into viral proteins. After being encapsidated into the nucleocapsid, HBV pgRNA is reverse transcribed to viral DNA by the viral polymerase. The newly formed rcDNA is either recycled to the nucleus to amplify the cccDNA pool or enveloped by viral surface proteins and secreted as virions (Grimm et al., 2011; Hao et al., 2015). HBV gene expression is controlled mainly at the transcriptional level by recruitment of a whole set of cellular transcription factors (TFs) and co-activators to support viral transcription. Some liver-enriched transcription factors are required for the expression of several liver-specific genes and involve in the cell metabolism and known to be involved in the HBV transcriptional control: hepatic nuclear factors (HNFs) like HNF6 (Wang and Holterman, 2012; Hao et al., 2015); PGC-1α, a major metabolic regulator of gluconeogenesis and lipogenesis (Jhuang et al., 2015); PPAR, which forms a heterodimer with the retinoid X receptor (RXR) to transcriptionally activate its target genes involved in fatty acid catabolism, gluconeogenesis, and lipoprotein assembly; farnesoid X receptor (FXR), which also forms a heterodimer with RXR and controls many aspects of lipid and cholesterol metabolism; and forkhead Box O1 (FOXO1, formerly FKHR), which is important for regulating glucose homeostasis. The nuclear receptor LXRA and cyclic-AMP response element-binding protein (CREB), involved in glucose and lipid metabolism by supporting the transcription of genes regulating those processes, also participate in the control of HBV transcription (Bar-Yishay et al., 2011; Kim et al., 2011). These transcription factors regulate HBV transcription by interacting with their respective binding sites within the HBV promoters and enhancers.

miRNAs ARE INVOLVED IN CONTROL OF HBV REPLICATION

Virus-host interactions may be mediated by cellular miRNAs to control gene expression. By transfecting antagonirs targeting 328 human miRNAs into HepG2 cells, Zhang et al. (2010) identified miR-199a-3p and miR-210 with the ability to suppress HBsAg expression. The direct effect of these two miRNAs on HBV RNA transcripts could be validated by GFP reporter assay. The seed sequence of miR-125a-5p was also found to be complementary paired with the coding sequence of HBV surface antigen, thus reducing the amount of secreted HBsAg (Potenza et al., 2011). Moreover, many cancer-related miRNAs, including miR-15a/-16-1 (Wang et al., 2013), -17-92 cluster (Khee et al., 2014), and -1236 (Huang et al., 2016), were recently shown to target HBV miRNAs directly by luciferase reporter assay and inhibit HBV replication. Besides the directly targeting to HBV genome, some cellular miRNAs, including epi-miRNAs, were found to be capable of inhibiting or stimulating HBV replication indirectly by regulating cellular transcription factors (Table 1). MiR-15b and –18a promoted HBV replication by augmenting HBV Enhancer I activity via direct targeting HNF1A and estrogen receptor alpha ESR1 respectively (Liu et al., 2009; Dai et al., 2014). Our group found that over-expression of epigenetically regulated miR-1 and -449a resulted in a marked increase in HBV replication, accompanied with up-regulated HBV transcription, antigen expression, and progeny secretion, primary through enhancement of transcriptional activity of the HBV core promoter by the nuclear receptor FXRA (Zhang et al., 2011; 2016). The miR-99 family including miR-99a, -99b, and -100 was also able to enhance HBV replication. However, this family had no influence on HBV promoter activities, different to miR-1 and -449a, but targeted autophagy.
through the Akt-mTOR pathway (Lin et al., 2016). Guo et al. (2011) found that miR-372 and -373 were positively related with HBV infection. They were upregulated in HBV-infected liver tissues and promote HBV gene expression through the pathway involving the transcription factor nuclear factor I/B (Gu et al., 2011). In contrast, there are several miRNAs reported negatively correlated with HBV replication. For example, miR-141 significantly suppressed HBV replication and gene expression through targeting PPARA in HepG2 cells (Hu et al., 2012). Restoration of miR-34c in hepatoma cells suppressed the transcription factor transforming growth factor-beta-induced factor homeobox 2 (TGIF2) expression, HBV replication, and viral antigen synthesis (Wang et al., 2015). Transfection of the miR-122 expression vector into the hepatoma cells could disturb HBV life cycle via repressing the transcription and expression of NDRG3 (Fan et al., 2011). miR-130a, -155, -370, and -939 may inhibit HBV replication via targeting transcription factors nuclear factor IA (NFIA), PPARG, CEBPA, and CEBPB, respectively (Huang et al., 2015; Sarkar et al., 2015; Chen et al., 2016; Fan et al., 2016).

On the other hand, viral infection may also cause miRNA expression alteration. Winther et al. (2013) have characterized the plasma miRNA profiles of children chronically infected with HBV and found there were differential plasma miRNA profiles in HBeAg positive and negative children with CHB. In hepatoma cell lines, HBV may change miRNA expression levels through HBx protein. An inverse correlation was noted between the expression of HBx and that of the let-7 family, including let-7a, -7b -7c, miR-122, -145, and -16 in HCC patients or in hepatoma cell lines (Wang et al., 2010; Wu et al., 2011; Peng et al., 2014; Gao et al., 2015). In contrast, a positive correlation between the expression of HBx and some miRNAs were also found. Over-expressing HBx enhanced miR-21 expression (Damania et al., 2014). The expression of miR-331-3p was enhanced by HBx through enhancement of its promoter activity (Cao et al., 2015).

### miRNAs LINK HBV LIFE CYCLE AND HOST CELL METABOLISM

Up to now, the majority of studies focused on the role of miRNA in HBV life cycle and host cell metabolism independently. Yet, the direct link of miRNA-metabolism-HBV replication needs to be examined in future study. miR-125b-5p is apparently associated with HBV infection (Winther et al., 2013; Li et al., 2015) and is able to regulate HBV replication via LIN28B/let-7 axis, which is a major pathway in the regulation of cell growth and metabolism (Zhu et al., 2011; Shyh-Chang and Daley, 2013; Ma et al., 2014). Transient transfection of miR-125b-5p into hepatoma cell lines resulted in upregulation of HBV replication and also in modulation of genes related to liver-specific metabolic functions, including UGT1A6, UGT1A9, UGT2A3, UGT2B10 and UGT2B15 (our own unpublished data). Besides, Huang et al. (2015) found miR-130a could inhibit HBV RNA transcription and DNA replication by targeting at two major metabolic regulators PGC1α and PPARγ, respectively. Both transcription factors are able to potently stimulate HBV replication (Huang et al., 2015). On the other hand, HBV infection may also induce abnormal host cell metabolism through affecting miRNA expression. Cui et al. (2014) found that HBx could suppress miR-205, which might contribute to the abnormal lipid metabolism through

---

**Table 1. MicroRNAs targeting TFs involved in HBV replication**

<table>
<thead>
<tr>
<th>Host miRNA</th>
<th>Regulating TFs</th>
<th>Effects on HBV replication</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-1</td>
<td>FXRA</td>
<td>upregulate</td>
<td>Zhang et al., 2011</td>
</tr>
<tr>
<td>miR-15b</td>
<td>HNF1A</td>
<td>upregulate</td>
<td>Dai et al., 2014</td>
</tr>
<tr>
<td>miR-18a</td>
<td>ESR1</td>
<td>upregulate</td>
<td>Liu et al., 2009</td>
</tr>
<tr>
<td>miR-372/373</td>
<td>NFIB</td>
<td>upregulate</td>
<td>Guo et al., 2011</td>
</tr>
<tr>
<td>miR-449a</td>
<td>CREBFXRA</td>
<td>upregulate</td>
<td>Zhang et al., 2016</td>
</tr>
<tr>
<td>miR-34c</td>
<td>TGIF2</td>
<td>downregulate</td>
<td>Wang et al., 2015</td>
</tr>
<tr>
<td>miR-122</td>
<td>NDRG3</td>
<td>downregulate</td>
<td>Fan et al., 2011</td>
</tr>
<tr>
<td>miR-130a</td>
<td>PPARA</td>
<td>downregulate</td>
<td>Huang et al., 2015</td>
</tr>
<tr>
<td>miR-141</td>
<td>PPARA</td>
<td>downregulate</td>
<td>Hu et al., 2012</td>
</tr>
<tr>
<td>miR-155</td>
<td>CEBPB</td>
<td>downregulate</td>
<td>Sarkar et al., 2015</td>
</tr>
<tr>
<td>miR-370</td>
<td>NFIA</td>
<td>downregulate</td>
<td>Fan et al., 2016</td>
</tr>
<tr>
<td>miR-939</td>
<td>CEBPA</td>
<td>downregulate</td>
<td>Chen et al., 2016</td>
</tr>
</tbody>
</table>
acyl-CoA synthetase long-chain family member 4 (ACSL4) in hepatoma cells.

CONCLUSION

miRNAs are thought to exert a profound effect on almost every aspect of liver biology and pathology. The interactions among miRNAs, HBV infection, and hepatocyte metabolism are complex but closely linked as indicated in Figure 1. Viral infection often changes host cell metabolic activities through affecting various cellular factors and pathways (line 5). The action of miRNAs represents one of the major central-regulatory principles (line 3 and 1). On the other hand, miRNAs regulate hepatocyte lipid and glucose metabolisms which are closely related to HBV replication (line 1 and 4). Moreover, miRNAs may also regulate HBV replication via binding to HBV genome directly or modulation of HBV-related transcriptional factors to indirectly regulate HBV enhancer or promoter activities (line 2). Despite of the progress in drug discovery and development, the clinical use of direct-acting antivirals against HBV is still very limited. Therefore, the development of effective, well tolerated, and affordable antiviral treatment is crucial to control chronic HBV infection, cirrhosis, and HCC (Mizuguchi et al., 2015). The viral-induced abnormal miRNA expression and host metabolic alteration suggests that miRNAs may serve as potential targets for treatment of HBV infection and HBV-associated HCC. Finally, miRNAs are able to regulate virus replication and therefore, could be explored for novel strategies for therapeutic approaches.

COMPLIANCE WITH ETHICS GUIDELINES

The author declares that they have no competing interests. This article does not contain any study with human or animal subjects performed by any of the authors.

REFERENCES


